PCN119 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.256
https://www.valueinhealthjournal.com/article/S1098-3015(20)32512-2/fulltext
Title :
PCN119 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32512-2&doi=10.1016/j.jval.2020.08.256
First page :
Section Title :
Open access? :
No
Section Order :
10204